MADRIGAL PHARMACEUTICALS, INC. Selling, General and Administrative Expense
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Selling, General and Administrative Expense of $289.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $289.38M, a 47.00% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $268.52M, a 59.95% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $239.98M, a 69.93% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $209.12M, a 94.37% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2025 was $813.83M, a 87.06% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2024 was $435.06M, a 302.29% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2023 was $108.15M, a 124.70% increase from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2022 was $48.13M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $289.38M 10-Q · filed 2026-07-30 | $557.90M 10-Q · filed 2026-07-30 | $797.87M derived: sum of 3 quarters · filed 2026-07-30 | $1.01B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $268.52M 10-Q · filed 2026-05-06 | $508.50M derived: sum of 2 quarters · filed 2026-05-06 | $717.61M derived: sum of 3 quarters · filed 2026-05-06 | $914.47M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $239.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $449.09M derived: sum of 2 quarters · filed 2026-02-19 | $645.95M derived: sum of 3 quarters · filed 2026-07-30 | $813.83M 10-K · filed 2026-02-19 |
| 2025-09-30 | $209.12M 10-Q · filed 2025-11-04 | $405.98M derived: sum of 2 quarters · filed 2026-07-30 | $573.85M 10-Q · filed 2025-11-04 | $715.07M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $196.86M 10-Q · filed 2026-07-30 | $364.73M 10-Q · filed 2026-07-30 | $505.96M derived: sum of 3 quarters · filed 2026-07-30 | $613.54M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $167.88M 10-Q · filed 2026-05-06 | $309.10M derived: sum of 2 quarters · filed 2026-05-06 | $416.68M derived: sum of 3 quarters · filed 2026-05-06 | $522.13M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $141.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $248.81M derived: sum of 2 quarters · filed 2026-02-19 | $354.26M derived: sum of 3 quarters · filed 2026-02-19 | $435.06M 10-K · filed 2026-02-19 |
| 2024-09-30 | $107.58M 10-Q · filed 2025-11-04 | $213.03M derived: sum of 2 quarters · filed 2025-11-04 | $293.83M 10-Q · filed 2025-11-04 | $340.37M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $105.45M 10-Q · filed 2025-08-05 | $186.25M 10-Q · filed 2025-08-05 | $232.78M derived: sum of 3 quarters · filed 2026-02-19 | $260.37M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $80.80M 10-Q · filed 2025-05-01 | $127.34M derived: sum of 2 quarters · filed 2026-02-19 | $154.92M derived: sum of 3 quarters · filed 2026-02-19 | $172.76M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $46.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $74.12M derived: sum of 2 quarters · filed 2026-02-19 | $91.96M derived: sum of 3 quarters · filed 2026-02-19 | $108.15M 10-K · filed 2026-02-19 |
| 2023-09-30 | $27.58M 10-Q · filed 2024-10-31 | $45.43M derived: sum of 2 quarters · filed 2024-10-31 | $61.61M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $17.84M 10-Q · filed 2024-08-07 | $34.03M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $16.18M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $48.13M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |